CD274 and hepatocellular carcinoma: At present, treatments involving the use of immune checkpoint inhibitors (ICIs), such as those which target the programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) pathway, are currently a priority for research in the field of advanced HCC (6, 7).